产品
编 号：F155819
分子式：C25H28N6O3
分子量：460.53
分子式：C25H28N6O3
分子量：460.53
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1419609-94-1
产品详情
生物活性：
GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research.
体内研究：
GSK2798745 inhibits TRPV4 agonist-mediated lung edema in rats in a dose-dependent manner.Animal Model:TRPV4-mediated lung edema in male Sprague-Dawley rats
Dosage:0, 16, 50, or 150 ng/kg
Administration:Intravenous injection; 0, 16, 50, or 150 ng/kg per minute; 60 min
Result:Inhibited the formation of pulmonary edema, with complete inhibition seen at the highest dose tested where the basal lung wet weight to body weight ratio was held to control levels (LW/BW=4.21).
体外研究：
GSK2798745 inhibits TRPV4 agonist-induced impedance reduction in human umbilical vein endothelial cells (HUVECs).
GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research.
体内研究：
GSK2798745 inhibits TRPV4 agonist-mediated lung edema in rats in a dose-dependent manner.Animal Model:TRPV4-mediated lung edema in male Sprague-Dawley rats
Dosage:0, 16, 50, or 150 ng/kg
Administration:Intravenous injection; 0, 16, 50, or 150 ng/kg per minute; 60 min
Result:Inhibited the formation of pulmonary edema, with complete inhibition seen at the highest dose tested where the basal lung wet weight to body weight ratio was held to control levels (LW/BW=4.21).
体外研究：
GSK2798745 inhibits TRPV4 agonist-induced impedance reduction in human umbilical vein endothelial cells (HUVECs).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备